Multi-Marker Tumor Panel Guide: Precision Cancer Detection
Multi-Marker Tumor Panel Guide: Precision Cancer Detection
Serum tumor markers are proteins and related analytes that support cancer management, including tracking disease progression, assessing treatment response, and detecting recurrence after treatment. Used one at a time, they carry well-documented gaps: sensitivity that drops in early-stage disease, specificity that suffers in benign inflammation, and population-level blind spots. Multi-marker tumor panels exist to close those gaps. This guide examines how combined detection works, which panels address which clinical questions, and how Poclight's Tumor Marker portfolio — anchored by tPSA, fPSA, CEA, and complementary analytes — is delivered on a compact detection platform.
Why Single Markers Fall Short
The limitations of individual markers are measurable and specific, and they define exactly where a panel adds value.
AFP (Alpha-Fetoprotein) is a hepatocellular carcinoma diagnostic and screening marker, yet it shows low sensitivity in early HCC with 30–40% false negatives. Relying on AFP alone can therefore miss early-stage disease.
CA19-9 (Carbohydrate Antigen 19-9) offers 74–79% sensitivity for pancreatic cancer but produces false negatives in Lewis antigen-negative individuals, representing 5–10% of the population. A single marker also has limited specificity for cancer localization.
CA125 (Cancer Antigen 125) is elevated in 80% of advanced ovarian cancer cases but in only 50% of early-stage cases, which constrains early detection when it is used alone.
tPSA (Total Prostate-Specific Antigen) triggers further investigation above 4 ng/mL, but its low specificity in benign prostatic hyperplasia and prostatitis can create unnecessary biopsy burden. Values in the 4–10 ng/mL gray zone are inherently ambiguous.
CYFRA21-1 (Cytokeratin 19 Fragment) shows, by itself, a less positive correlation in NSCLC prognosis, and a single marker may not distinguish early-stage NSCLC from benign lung disease presenting with suspicious pulmonary masses.
How Combined Detection Improves Performance
Two definitions frame the entire field. Sensitivity is the ability to correctly identify cancer cases. Specificity is the ability to correctly exclude non-cancer cases. Combined marker panels are designed to raise both by compensating for the limitations of individual markers.
In prostate cancer, the tPSA and fPSA pair illustrates the principle precisely. When tPSA sits in the 4–10 ng/mL gray zone, calculating the fPSA/tPSA ratio — with a ratio below 0.16 — increases prostate cancer detection specificity by 17.4% and reduces unnecessary biopsies. The underlying biology is PSA isoform differentiation: fPSA tends to be higher in benign conditions and lower in malignancies.
In hepatocellular carcinoma, combining AFP with AFP-L3 and DCP lifts early detection sensitivity to 70–85% and specificity to 80–90%, supporting earlier detection than AFP alone.
In NSCLC, CYFRA21-1 combined with SCC reaches 88% sensitivity and 74% specificity and helps distinguish squamous from adenocarcinoma, while CEA plus SCC helps distinguish early-stage NSCLC from benign lung disease presenting with suspicious pulmonary masses. Adding CEA and CA125 to the mix detects early-stage NSCLC adenocarcinoma at 75% sensitivity and 70% specificity.
The Poclight Clinical Combined Detection Portfolio
Poclight organizes this evidence into eight defined combined detection panels, each mapped to a cancer type and a clinical department.
The Prostate Cancer Combined Detection Panel (tPSA + fPSA, F/T ratio) functions as a reflex panel for men with tPSA of 4–10 ng/mL, reducing false positives by 30% in the gray zone, with panel sensitivity of 44–67% and specificity of 81–87%.
The Hepatocellular Carcinoma Combined Detection Panel (AFP + AFP-L3 + DCP) delivers 70–85% sensitivity and 80–90% specificity for early detection.
Two lung panels serve distinct questions. The NSCLC Squamous Combined Detection Panel (CYFRA21-1 + SCC) reaches 88% sensitivity and 74% specificity to distinguish squamous from adenocarcinoma, while the NSCLC Adenocarcinoma Combined Detection Panel (CEA + CYFRA21-1 + CA125) provides 75% sensitivity and 70% specificity for early-stage adenocarcinoma detection.
Three gastrointestinal panels follow. The Gastric Cancer Combined Detection Panel (CEA + CA19-9 + CA72-4) achieves 70–86% sensitivity and 80–88% specificity, with CA72-4 contributing gastric-origin specificity. The Pancreatic Cancer Combined Detection Panel (CEA + CA19-9 + CA125) reaches 82% sensitivity and 75% specificity, improves on CA19-9 alone, and can help predict resectability. The Colorectal Cancer Combined Detection Panel (CEA + CA19-9 + CA242) delivers 70–92% sensitivity and 85–90% specificity for post-surgical monitoring and the detection of liver metastases.
The Ovarian Cancer Combined Detection Panel (CA125 + HE4) rounds out the portfolio with 76–94% sensitivity, 75–95% specificity, and 93.8% accuracy, supporting early detection and recurrence monitoring. Combining CA125 with HE4 improves specificity to 95% through the ROMA index.
The Individual Markers Behind the Panels
Each panel is built from individually validated Poclight Tumor Marker tests. CEA (Carcinoembryonic Antigen) is a pan-cancer monitoring marker for colorectal, gastric, pancreatic, lung, and breast cancers; serial postoperative measurements predict recurrence, and a rising CEA can precede imaging findings. U.S. clinical practice guidelines recommend obtaining a CEA level before elective colon cancer surgery for post-surgical risk management. Its documented limitation is low specificity in smokers and inflammation, so it is not diagnostic by itself.
tPSA remains organ-specific, with levels correlating to tumor burden and metastasis risk. fPSA serves as its companion for refining detection in the gray zone. AFP levels above 400 ng/mL with imaging confirm hepatocellular carcinoma, and the combination of AFP with AFP-L3 and DCP supports earlier detection.
Delivery on the C5000 Dry Micro System
Poclight's panels run on the C5000 Dry Micro System, a semi-automatic, portable dry micro detection system for rapid serum tumor marker testing. It returns a first sample result in 3 minutes across 7 channels, with throughput of 80 tests per hour and a weight of 8.5 kg or less. The platform reports a coefficient of variation below 3% at the instrument level, against a platform technical metric of CV below 5%.
Its dry micro reagent format uses lyophilized reagents with room temperature storage and transport, alongside liquid complementary reagents, and applies wash-free separation with no magnetic beads and no complex liquid path — reducing complexity and operating cost. Operation is through a touch screen, and the system supports LIS/HIS transmission with real-time information sharing.
Clinical Consensus Supporting Combined Detection
Guideline and consensus support is consistent across the portfolio's core markers. PSA Consensus 2024 (UK) describes the PSA blood test as the first step in the prostate cancer diagnostic pathway — a low-cost, safe, and effective way of identifying men who would benefit from further testing. A Chinese expert consensus on HCC screening cost-effectiveness highlighted biannual ultrasound and AFP as a cost-effective strategy. A further Chinese expert consensus concluded that CYFRA21-1 alone shows less positive correlation in NSCLC prognosis, while combining CEA and SCC helps distinguish early-stage NSCLC from benign lung disease.
Conclusion
A multi-marker tumor panel is not a broader test for its own sake. It is a structured response to documented gaps in sensitivity and specificity. Poclight's portfolio pairs defined panels — spanning prostate, liver, lung, gastric, pancreatic, colorectal, and ovarian cancer — with individual Tumor Marker tests and a portable detection system built for rapid turnaround, covering urology, gastrointestinal surgery, gynecology, oncology, respiratory, hepatobiliary surgery, and gastroenterology.
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd
About Author
